


a.) Amendment to the Claims

Claims 1-5 (Cancelled).

6. (Currently Amended) The method of treating prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 5, Claim 17 or 18, wherein Y¹ and Y² each is a hydrogen atom.

Claims 7-14 (Cancelled).

15. (Currently Amended) A method of ~~preventing and/or~~ treating ~~diseases accompanied by~~ chronic musculoskeletal pain which comprises administering to a patient in need thereof an effective amount of a compound represented by formula (1)




(1)

having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt thereof.

Claim 16 (Cancelled).

17. (Currently Amended) The method for treating prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed Claim 7, wherein R¹ and R² each is ethyl which comprises as an active ingredient a compound having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt thereof, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a xanthine derivative represented by formula (I):




wherein


R¹ and R² are each ethyl;

R³ represents a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl;

R⁴ represents formula (II):




(wherein Y¹ and Y² independently represent a hydrogen atom, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl or a group represented by formula (III);



(wherein R⁶ represents a hydrogen atom, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3)); and

X¹ and X² each represent an oxygen atom.

18. (Currently Amended) The method for treating prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed Claim 8, wherein R¹ and R² each is ethyl which comprises as an active ingredient a compound having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt thereof, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a xanthine derivative represented by formula (I);




wherein

R¹ and R² are each ethyl;


R³ represents a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl;

R⁴ represents formula (II);




(wherein Y¹ and Y² independently represent a hydrogen atom, halogen or lower alkyl; and

Z represents a group represented by formula (IV);



(wherein at least one of R⁷, R⁸ and R⁹ represents lower alkyl or lower alkoxy and the remaining groups represent a hydrogen atom; R¹⁰ represents a hydrogen atom or lower alkyl)

or formula (III);




(wherein R⁶ represents a hydrogen atom, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3); and

X¹ and X² each represent an oxygen atom.

19. (Currently Amended) The method for treating prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 17, wherein R³ is methyl.

20. (Currently Amended) The prophylactic and/or therapeutic agent for method for treating diseases accompanied by chronic musculoskeletal pain as claimed in Claim 18, wherein R³ is methyl.

21. (New) A method of treating hyperalgesia which comprises administering to a patient in need thereof an effective amount of a compound represented by formula (1)



(1)

or a pharmaceutically acceptance salt thereof.

22. (New) The method for treating chronic musculoskeletal pain as claimed in Claim 6, wherein R³ is methyl.